Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €50.37 EUR
Change Today +0.58 / 1.16%
Volume 0.0
MAH1 On Other Exchanges
As of 2:03 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

magellan health inc (MAH1) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/14/15 - €67.23
52 Week Low
10/8/14 - €41.72
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MAGELLAN HEALTH INC (MAH1)

magellan health inc (MAH1) Related Bloomberg News

View More Bloomberg News

magellan health inc (MAH1) Related Businessweek News

No Related Businessweek News Found

magellan health inc (MAH1) Details

Magellan Health, Inc. engages in the healthcare management business in the United States. The company’s Managed Healthcare Commercial segment offers managed behavioral healthcare services, as well as employee assistance programs services. Its Managed Healthcare Public Sector segment is involved in the management of behavioral health services for recipients under contracts with state and local governmental agencies; and integrated management of physical, behavioral, and pharmaceutical care for special populations covered under Medicaid and other government sponsored programs. The company’s Specialty Solutions segment provides specialty solutions, such as the delivery of diagnostic imaging and various other specialty areas comprising radiation oncology, obstetrical ultrasound, cardiology, and musculoskeletal management. This segment offers specialty solutions under contracts with health plans and insurance companies for its commercial, Medicaid, and Medicare members. Its Pharmacy Management segment provides pharmacy management products and solutions that offer clinical and financial management of drugs paid under medical and pharmacy benefit programs, including traditional pharmacy benefit management (PBM); pharmacy benefit administration for state Medicaid and other government sponsored programs; specialty pharmaceutical dispensing operations, and contracting and formulary optimization programs; medical pharmacy management programs; and programs for the management of specialty drugs, which treat complex conditions, as well as subcontract arrangements to provide PBM services for public sector customers. The company offers its services to health plans, managed care organizations, employers, labor unions, various military and governmental agencies, third party administrators, consultants, brokers, and insurance companies. Magellan Health, Inc. was founded in 1969 and is based in Scottsdale, Arizona.

6,600 Employees
Last Reported Date: 02/26/15
Founded in 1969

magellan health inc (MAH1) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $975.0K
Chief Financial Officer
Total Annual Compensation: $496.8K
Chief Executive Officer of Magellan Healthcar...
Total Annual Compensation: $518.8K
General Counsel and Secretary
Total Annual Compensation: $430.2K
Compensation as of Fiscal Year 2014.

magellan health inc (MAH1) Key Developments

Magellan Health, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Second Half and Full Year of 2015

Magellan Health, Inc. reported earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported adjusted net income was $14.7 million, and adjusted EPS was $0.56 per share on a diluted basis. For the second quarter of 2014, adjusted net income was $11.8 million, and adjusted EPS was $0.42 per share. The increase in adjusted net income between periods was mainly due to the increase in segment profit. Approximately half of this year-over-year revenue increase is attributable to revenue from acquired entities. The remaining revenue increase resulted primarily from the impact of new business, same-store growth and rate increases, which were partially offset by the loss of revenues associated with previously announced contract terminations. Net income attributable to the company was $4.64 million or $0.17 per diluted share compared to $4.99 million or $0.18 per diluted share for the same quarter ended June 30, 2014. Total net revenue for the second quarter ended June 30, 2015 was $1.16 billion, compared to $888.01 million for the same quarter ended June 30, 2014. For six months, the company reported adjusted net income of $39.1 million, adjusted EPS of $1.47 and segment profit of $118.1 million. Results for this quarter reflect strong performance from Pharmacy segment, solid results in Specialty Solutions and some weakness in care results in the Commercial and Public Sector segments. GAAP cash flow from operations was $112.7 million compared to cash flow from operations of $137.1 million for the prior year year-to-date period. GAAP cash flow includes a shift between restricted cash and restricted investments, which affects the sources and uses of cash from operations and from investing activities. Adjusting for the impact of these shifts, cash flow from operations for the 6 months ended June 30, 2015, was $49.5 million compared to $124.8 million for the prior year period. The decrease of $75.3 million in operating cash flows is mainly due to net unfavorable working capital and other changes between periods of $80.8 million. Net income attributable to the company was $11.93 million, or $0.45 per diluted share, compared to $30.71 million, or $1.10 per diluted share, for the same period ended June 30, 2014. Total net revenue for the six months ended June 30, 2015 was $2.14 billion compared to $1.85 billion for the same period ended June 30, 2014. For 2015, the company expects fully diluted EPS to be between $1.69 and $2.28 and fully diluted adjusted EPS between $3.45 and $3.90 based on average fully diluted shares of 26.7 million. This updated fully diluted share count reflects share repurchases and option exercises through July 22, but excludes any potential future activity. For the second half of 2015, the company expects to produce stronger earnings due to the following factors: improved results in MCC, mainly driven by care management initiatives, network re-contracting and rates; the impact of business growth, primarily in pharmacy; and seasonality and timing of care results and customer settlements across businesses.

Magellan Health, Inc. Announces Board Changes

Magellan Heath, Inc. reported that its lead director, Robert Le Blanc, retired from the board of directors on July 23, 2015. Also on July 23, 2015, the board approved a reduction of the size of the board from 10 to 9 members and appointed William McBride, a member of the board since 2004, as its new lead director.

Magellan Health, Inc. to Report Q2, 2015 Results on Jul 27, 2015

Magellan Health, Inc. announced that they will report Q2, 2015 results at 10:00 AM, US Eastern Standard Time on Jul 27, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MAH1:GR €50.37 EUR +0.58

MAH1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amedisys Inc $38.64 USD -0.45
Kindred Healthcare Inc $20.08 USD -0.55
LifePoint Health Inc $78.13 USD -1.96
Select Medical Holdings Corp $12.90 USD -0.09
Universal American Corp/NY $7.15 USD -0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation MAH1 Industry Range
Price/Earnings 25.2x
Price/Sales 0.4x
Price/Book 1.3x
Price/Cash Flow 9.8x
TEV/Sales 0.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MAGELLAN HEALTH INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at